Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zila's OraTest Rinse Needs Additional Study, FDA Advisory Committee Says

This article was originally published in The Gray Sheet

Executive Summary

Zila should conduct another trial of its OraTest oral cancer diagnostic, FDA's Oncology Drugs Advisory Committee determined Jan. 13.

You may also be interested in...

Zila’s OraTest Oral Cancer Screen Lags At CDER; ZTC Clears Premarket Hurdle

Zila Medical's strategy of seeking an adjunctive claim for its ZTC tolonium chloride compound enabled a relatively quick device review, CEO Douglas Burkett said in a Feb. 7 conference call

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts